MedTrace Logo

Straberi Epistamp Device for Postinflammatory Hyperpigmentation

NCT04740255 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2023-12-06

No results posted yet for this study

Summary

This pilot study will expand knowledge and application needling using the Straberi device for the improvement of Postinflammatory Hyperpigmentation (PIH) caused by acne.

Conditions

  • Postinflammatory Hyperpigmentation

Interventions

DEVICE

Straberi Epistamp

The patient's entire face will be treated. The following settings will be used as a treatment protocol. Needle length between .02- 1.55 mm

Sponsors & Collaborators

  • Lavish Beauty

    collaborator UNKNOWN

  • Universal Skincare Institute

    lead OTHER

Principal Investigators

  • Maurice E Wright, MD · Columbia University

  • Leslie L Nesbitt · Universal Skincare

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-12-23
Primary Completion
2023-06-30
Completion
2023-10-12
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04740255 on ClinicalTrials.gov